Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: Implication for clinical drug-drug interactions

D O I：

10.1007/s12038-011-9143-9

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Podophyllotoxin (PPT) and its derivatives exert significant anti-cancer activities, and one derivative etoposide is often utilized to treat various cancers in the clinic. The aim of the present study is to investigate the inhibitory effects of PPT on major cytochrome P450 (GYP) isoforms in human livers. Inhibition of CYP3A4, CYP2C9, CYP2C8, CYP2D6, CYP2E1 and CYP2A6 by PPT was investigated in the human liver microsomal system. Time-dependent inhibition of CYP3A4 by PPT was also evaluated. The results showed that PPT strongly exhibited inhibitory effects on CYP3A4 and CYP2C9 in a concentration-dependent manner. Half inhibition concentration (IC(50)) was 1.1 +/- 0.3 and 4.6 +/- 0.3 mu M for CYP3A4 and CYP2C9, respectively. Inhibition kinetic analysis showed that PPT exhibited competitive inhibition towards CYP3A4 and CYP2C9 with K(i) of 1.6 and 2.0 mu M, respectively. Additionally, PPT exerted time-dependent inhibition towards CYP3A4 and the kinetic parameters were 4.4 +/- 2.1 mu M and 0.06 +/- 0.01 min(-1) for K(I) and ki(nact), respectively. Our experimental data indicate that potential drug-drug interaction (DDI) might exist when PPT is co-administered with the substrates which mainly undergo CYP3A4- or CYP2C9-mediated metabolism.

引用

页码：879 / 885

页数：7

共 32 条

[1] Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers [J].

Alderman, J ;

Preskorn, SH ;

Greenblatt, DJ ;

Harrison, W ;

Penenberg, D ;

Allison, J ;

Chung, M .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1997, 17 (04) :284-291

[2] Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics [J].

Belle, DJ ;

Ernest, CS ;

Sauer, JM ;

Smith, BR ;

Thomasson, HR ;

Witcher, JW .

JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :1219-1227

[3] Enzyme-assisted asymmetric total synthesis of (-)-podophyllotoxin and (-)-picropodophyllin [J].

Berkowitz, DB ;

Choi, S ;

Maeng, JH .

JOURNAL OF ORGANIC CHEMISTRY, 2000, 65 (03) :847-860

[4] Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].

Bertelsen, KM ;

Venkatakrishnan, K ;

Von Moltke, LL ;

Obach, RS ;

Greenblatt, DJ .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293

[5] The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective [J].

Bjornsson, TD ;

Callaghan, JT ;

Einolf, HJ ;

Fischer, V ;

Gan, L ;

Grimm, S ;

Kao, J ;

King, SP ;

Miwa, G ;

Ni, L ;

Kumar, G ;

McLeod, J ;

Obach, SR ;

Roberts, S ;

Roe, A ;

Shah, A ;

Snikeris, F ;

Sullivan, JT ;

Tweedie, D ;

Vega, JM ;

Walsh, J ;

Wrighton, SA .

JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) :443-469

[6] INHIBITION BY PAROXETINE OF DESIPRAMINE METABOLISM IN EXTENSIVE BUT NOT IN POOR METABOLIZERS OF SPARTEINE [J].

BROSEN, K ;

HANSEN, JG ;

NIELSEN, KK ;

SINDRUP, SH ;

GRAM, LF .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 44 (04) :349-355

[7] Etoposide: Four decades of development of a topoisomerase II inhibitor [J].

Hande, KR .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (10) :1514-1521

[8] Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes [J].

Hanioka, N ;

Ozawa, S ;

Jinno, H ;

Tanaka-Kagawa, T ;

Nishimura, T ;

Ando, M ;

Sawada, JI .

DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :391-396

[9] Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers [J].

Hemeryck, A ;

Lefebvre, RA ;

De Vriendt, C ;

Belpaire, FM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (03) :283-291

[10] Discovery of podophyllotoxins [J].

Imbert, TF .

BIOCHIMIE, 1998, 80 (03) :207-222

← 1 2 3 4 →